In 2018, as part of a new focus on advancing the treatment of lung cancer, BTG invested $20m in Veran Medical Technologies, Inc. BTG is a global healthcare company focused on Interventional Medicine and Veran is a privately held medical device company whose mission is to empower physicians to diagnose cancer earlier and to enable precision therapy to save lives.
Veran Medical CEO Jason Pesterfield said,
“BTG and Veran have the shared goal of helping physicians diagnose and treat lung cancer earlier in order to save lives.”
“Izy Capital is a rare breed of early stage venture and advisory that understands the complexities of modern financing, entrepreneurship and global delivery. Their reach is extraordinary, as is their vision. I never feel that Dave and the team have anything other than our interests at the core of everything they do”
Geryn Evans, CEO Project Blu
“David and the whole Izy Capital team are, simply, great partners. Approachable, direct, and always mindful of the risk/reward relationship in our growth, their vision, modelling and process management is exemplary. Dave always sees the bigger picture and endgame and above all deals with everyone with a level of humility which is so refreshing”
Phil Davies, CEO Flyform
Izy and more specifically David has enabled us to be laser focussed on delivery and customer segmentation. In a competitive market segment Dave has guided us to create a value proposition and outcomes orientated approach that is aligned with our mission of helping 500m to be more Mindful in their approach to life and others by 2025